ciprofloxacin + rifampicin + vancomycin

This is a combination of three antibiotics—ciprofloxacin, rifampicin (also known as rifampin), and vancomycin—used together for the treatment of severe or resistant bacterial infections. Each component has a distinct mechanism of action: - **Ciprofloxacin** is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. - **Rifampicin** is an ansamycin antibiotic that inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing RNA synthesis. - **Vancomycin** is a glycopeptide antibiotic that inhibits cell wall biosynthesis in Gram-positive bacteria by binding to D-Ala-D-Ala termini of cell wall precursor units. This combination may be considered in complex infections such as prosthetic joint infections (PJI), endocarditis, osteomyelitis, or device-related infections caused by multidrug-resistant organisms like Staphylococcus aureus (including MRSA) or coagulase-negative staphylococci. The rationale for combining these agents includes broadening antibacterial coverage and reducing the risk of resistance emergence; however, clinical evidence suggests variable efficacy depending on infection type and pathogen susceptibility[1][2][4]. Adverse effects can include nephrotoxicity (vancomycin), hepatotoxicity (rifampicin), gastrointestinal disturbances, rash, and potential drug-drug interactions.